Drugs / ONT01
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07107659 | Sep 2026 → May 2030 expected | lupus nephritis, systemic lupus erythematosus | Hospital for Special Surgery, New York | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06904378 | Mar 2026 → Sep 2028 expected | pancreatic ductal adenocarcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONT01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07107659 ↗ |
| Modality | Small molecule | “ONT01 is a small molecule CD11b modulator.” NCT07107659 ↗ |
| Route | Oral | “ONT01 is an oral medication taken twice daily on Days 1-21 of each 28-day cycle.” NCT06904378 ↗ |